Autopsy report · NCT03690141
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Cause of deathFutility
“Terminated early due to a lack of efficacy.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 5 months before it stopped.
- 16 participants enrolled.
- Results were posted on the registry 4 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Effector Therapeutics
- Sponsor type
- Industry
- Conditions
- Castrate-resistant Prostate Cancer (CRPC)
- Interventions
- eFT508
- Participants
- 16
- Sites
- 10
- Countries
- United States
Trials that died the same way
- Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
“Terminated due to lack of efficacy” - Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
“Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.” - Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
“terminated early for administrative reasons unrelated to safety or efficacy” - A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
“The study was early terminated due to lack of efficacy.” - Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
“Study was terminated early due to a lack of improved efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.